Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences Inc (NASDAQ: PLSE) pioneers bioelectric medicine through its proprietary Nano-Pulse Stimulation technology, offering investors and medical professionals a novel approach to non-thermal therapies. This dedicated news hub provides real-time updates on clinical advancements, regulatory developments, and strategic partnerships shaping the future of targeted cellular treatments.
Access verified information about PLSE's progress in immuno-oncology applications, dermatology research breakthroughs, and system commercialization efforts. Our curated feed includes earnings reports, FDA submissions, peer-reviewed study results, and executive commentary – all essential for evaluating the company's position in the electroceuticals market.
Key updates cover therapeutic trial milestones, intellectual property expansions, and collaborations with leading medical institutions. Bookmark this page to monitor how PLSE's drug-free energy modalities could transform treatment protocols for complex conditions while driving long-term value in the medical device sector.
Pulse Biosciences (NASDAQ: PLSE) has appointed Kevin Danahy as its new Chief Commercial Officer (CCO). Danahy brings over 20 years of experience in medical technology, having previously driven revenue growth at Solmetex and held significant roles at Zimmer Biomet and Intuitive Surgical. His expertise is expected to enhance market penetration for the CellFX® System, which utilizes proprietary Nano-Pulse Stimulation technology to improve dermatologic outcomes. As part of his appointment, Danahy received 300,000 stock options, subject to performance-based criteria.
Pulse Biosciences, Inc. (NASDAQ: PLSE) has updated its FDA 510(k) submission to include treatment of sebaceous hyperplasia using the CellFX® System. Originally submitted in December 2021, the application received an Additional Information letter from the FDA on February 5, 2022, citing insufficient clinical evidence. The company plans to meet with the FDA in Q1 2022 to discuss the next steps, which may require more clinical data or a new submission. The CellFX System is currently approved in Europe for several dermatological conditions but faces challenges in the U.S. market.
Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The company will host investor meetings on February 15-16, 2022. Pulse Biosciences specializes in bioelectric medicine, focusing on health innovations to enhance patient quality of life. Their flagship product, the CellFX® System, utilizes proprietary Nano-Pulse Stimulation™ technology to effectively treat various dermatologic conditions while preserving surrounding tissues. For more details, visit pulsebiosciences.com.
Pulse Biosciences (PLSE) announced preliminary unaudited financial results for Q4 2021, estimating full-year revenue between
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced its participation in the Stephens Annual Investment Conference in Nashville, Tennessee, scheduled for December 2, 2021. Management will engage in a fireside chat at 2:00 PM PT / 4:00 PM CT. Interested individuals can access the live and recorded webcast via the company’s website.
Pulse Biosciences specializes in bioelectric medicine, leveraging its CellFX® System and Nano-Pulse Stimulation™ technology to improve dermatologic outcomes.
Pulse Biosciences, Inc. (Nasdaq: PLSE) announced its third quarter 2021 financial results, reporting revenue of $574,000, with 12 Controlled Launch Program participants opting to acquire CellFX Systems for commercial use. The company onboarded a total of 68 participants and completed patient enrollment for key clinical studies. Operating expenses increased to $14.1 million, with a GAAP net loss of $14.3 million. Cash reserves totaled $42 million as of September 30, 2021. The company aims to expand the CellFX System's applications beyond dermatology.
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced its participation in the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 1:40 pm PT / 4:40 pm ET. The company, known for its innovative bioelectric medicine, aims to enhance patient care through its CellFX® System and Nano-Pulse Stimulation™ (NPS™) technology. The CellFX System treats dermatologic conditions effectively while preserving surrounding tissue. Interested parties can access the on-demand webcast via the Company’s website.
Pulse Biosciences, Inc. (NASDAQ: PLSE) will release its financial results for Q3 2021 on November 15, 2021, after market close. A conference call is scheduled at 1:30 PM PT for investors to discuss the results. The company is known for its innovative Nano-Pulse Stimulation™ (NPS™) technology, with its first commercial product, the CellFX® System, addressing dermatologic conditions. The system offers a multi-application platform with a utilization-based revenue model, aiming to enhance patient care and outcomes.
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced the appointment of Laureen DeBuono to its Board of Directors, succeeding Kenneth Clark, who has resigned. DeBuono brings extensive executive experience in driving growth and shareholder value in life sciences and medical technology sectors. She has previously held positions at Rodan+Fields and served as CEO of govino, LLC. Her appointment aims to enhance the commercial growth of the CellFX® System in dermatology and expand the company’s multi-specialty bioelectric medicine profile.
Pulse Biosciences (NASDAQ: PLSE) announces its participation in the H.C. Wainwright Global Investment Conference on September 14, 2021. Management will hold one-on-one meetings and the event will feature a presentation webcast available starting on September 13, 2021, at 7:00 am ET. The company's CellFX® System, utilizing Nano-Pulse Stimulation™ technology, aims to improve dermatologic outcomes by treating various conditions while preserving adjacent non-cellular tissue. More information can be found on CellFX.com.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
